These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 33624121

  • 1. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathôt R.
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [Abstract] [Full Text] [Related]

  • 2. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T, van Spengler MWF, Meijer K, Fijnvandraat K, Fischer K, Leebeek FWG, Cnossen MH, Mathôt RAA.
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [Abstract] [Full Text] [Related]

  • 3. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y, Roberts J, Bensen-Kennedy D, Jacobs I, Santagostino E, Voigt C, Feussner A, Morfini M, Sidhu J.
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.
    Simpson ML, Kulkarni R, Escuriola Ettingshausen C, Medom Meldgaard R, Cooper DL, Klamroth R.
    J Blood Med; 2019 Nov; 10():391-398. PubMed ID: 32009825
    [Abstract] [Full Text] [Related]

  • 8. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E.
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [Abstract] [Full Text] [Related]

  • 10. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M, Bergin C, Quinn E, Singleton E, Roche S, Benson J, Bird R, Byrne M, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM.
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
    van der Flier A, Hong V, Liu Z, Piepenhagen P, Ulinski G, Dumont JA, Orcutt KD, Goel A, Peters R, Salas J.
    Blood Coagul Fibrinolysis; 2023 Sep 01; 34(6):353-363. PubMed ID: 37577860
    [Abstract] [Full Text] [Related]

  • 12. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ, Alvir J, McDonald M, Spurden D, Fogarty PF, Chhabra A, Pleil AM.
    J Manag Care Spec Pharm; 2018 Jul 01; 24(7):643-653. PubMed ID: 29363389
    [Abstract] [Full Text] [Related]

  • 13. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
    Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A.
    Curr Med Res Opin; 2020 Jan 01; 36(1):9-15. PubMed ID: 31469321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
    Preijers T, Hazendonk HCAM, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA.
    J Thromb Haemost; 2017 Sep 01; 15(9):1737-1746. PubMed ID: 28688133
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.
    Haemophilia; 2019 Jul 01; 25(4):668-675. PubMed ID: 30993845
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
    Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG).
    Thromb Haemost; 2017 Jun 02; 117(6):1023-1030. PubMed ID: 28357444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.